European journal of cancer (Oxford, England : 1990) · 2025
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation-positive non-squamous, advanced non-small cell lung cancer (NSCLC) refractory to first-line osimertinib treatment: NEJ025B study.
СтатьяКлиническое исследование II фазыМногоцентровое исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nagashima Hiromi, Fukuhara Tatsuro, Utsumi Yu, Suzuki Aya, Miyanaga Akihiko, Seike Masahiro, Azuma Koichi, Asahina Hajime, Kisohara Akira, Kawashima Yosuke, Tanaka Hisashi, Kanemaru Ryota, Miyauchi Eisaku, Furuya Naoki, Sato Haruna, Nakashima Kazuhisa, Watanabe Satoshi, Sakai Kazuko, Nishio Kazuto, Takahashi Fumiaki, Kobayashi Kunihiko, Maemondo Makoto
Аннотация
BACKGROUND: Osimertinib is commonly used as a first-line treatment for EGFR-mutated advanced non-small cell lung cancer (NSCLC). However, the optimal treatment strategy following osimertinib failure remains unclear.
METHODS: Patients with EGFR-mutated NSCLC and exon 19 deletion or L858R mutation after failure of osimertinib treatment were assigned to a regimen of afatinib (20 mg daily) combined with carboplatin (AUC 5 mg/mL/min) and pemetrexed (500 mg/m2) every 3 weeks followed by maintenance treatment with afatinib plus pemetrexed, until disease progression or unacceptable toxicity was noted. The primary endpoint was the rate of progression-free survival (PFS) at 6 months after initiation of treatment (6M-PFSR).
RESULTS: Thirty-six patients were enrolled. One patient met the exclusion criteria, and the efficacy was evaluated in the remaining 35 patients. The 6M-PFSR, the primary endpoint, was 57.1 %. The confidence interval of 39.3-71.5 % exceeded the predefined threshold of 35 %, thereby meeting its primary endpoint. Notably, 28.6 % of patients achieved a long-term PFS of 1 year or longer. The objective response rate (ORR) was 51.4 %, the disease control rate (DCR) was 88.6 %, the median PFS was 8.2 months, the median duration of response (DOR) was 5.6 months, and the median overall survival (OS) was 22.5 months. The most common adverse events were diarrhea (52.8 %) and anorexia (47.2 %), both of which were predictable and manageable. Interstitial pneumonia developed in three patients (8.3 %), one of whom died. Another patient died from sepsis, bringing the total number of deaths in the study to two.
CONCLUSIONS: The combination of afatinib and the platinum doublet demonstrated satisfactory efficacy with manageable adverse events in tumors refractory to osimertinib, meeting its primary endpoint.
TRIAL REGISTRATION NUMBER: jRCTs021200005.
METHODS: Patients with EGFR-mutated NSCLC and exon 19 deletion or L858R mutation after failure of osimertinib treatment were assigned to a regimen of afatinib (20 mg daily) combined with carboplatin (AUC 5 mg/mL/min) and pemetrexed (500 mg/m2) every 3 weeks followed by maintenance treatment with afatinib plus pemetrexed, until disease progression or unacceptable toxicity was noted. The primary endpoint was the rate of progression-free survival (PFS) at 6 months after initiation of treatment (6M-PFSR).
RESULTS: Thirty-six patients were enrolled. One patient met the exclusion criteria, and the efficacy was evaluated in the remaining 35 patients. The 6M-PFSR, the primary endpoint, was 57.1 %. The confidence interval of 39.3-71.5 % exceeded the predefined threshold of 35 %, thereby meeting its primary endpoint. Notably, 28.6 % of patients achieved a long-term PFS of 1 year or longer. The objective response rate (ORR) was 51.4 %, the disease control rate (DCR) was 88.6 %, the median PFS was 8.2 months, the median duration of response (DOR) was 5.6 months, and the median overall survival (OS) was 22.5 months. The most common adverse events were diarrhea (52.8 %) and anorexia (47.2 %), both of which were predictable and manageable. Interstitial pneumonia developed in three patients (8.3 %), one of whom died. Another patient died from sepsis, bringing the total number of deaths in the study to two.
CONCLUSIONS: The combination of afatinib and the platinum doublet demonstrated satisfactory efficacy with manageable adverse events in tumors refractory to osimertinib, meeting its primary endpoint.
TRIAL REGISTRATION NUMBER: jRCTs021200005.